Gwenn Hansen
Fortune : 3 M $ au 31/08/2026
Fortune : 3 M $ au 31/08/2026
Gwenn M.
Hansen is Chief Scientific Officer at Nurix Therapeutics, Inc. since 2020, with employment at the company starting in 2015.
Formerly, served as Associate Professor at Baylor College of Medicine.
Education includes undergraduate studies at Gustavus Adolphus College and a doctorate from the University of Tennessee.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NURIX THERAPEUTICS, INC. 0,11 % | 01/09/2026 | 117 227 ( 0,11 % ) | 3 M $ | 31/08/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| NURIX THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/07/2019 |
| Sociétés | Poste | Fin |
|---|---|---|
Baylor College of Medicine
Baylor College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. BiotechnologyHealth Technology Operates as a a clinical stage biopharmaceutical company that discovers, develops and commercializes oral, small molecule therapies for the treatment of cancer & immune disorders | Health Technology |
Gustavus Adolphus College
Gustavus Adolphus College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Tennessee
University of Tennessee Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Baylor College of Medicine
Baylor College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national